To Evaluate the Efficacy and Safety of LuminoMark Injection in Patients With Nonpalpable Breast Lesions(Phase 3)
Status:
Completed
Trial end date:
2021-01-28
Target enrollment:
Participant gender:
Summary
This study is a multicenter, Randomized, Open-label, Parallel, Phase 3 Clinical Trial in 8
weeks for screening, once Investigational product injection, Follow up visit.